Residency · Residency · Medical Genetics Genomics

Mitochondrial Genetics and Maternal Inheritance

Mitochondrial Genome Structure

Organization

The human mitochondrial genome is a circular, double-stranded DNA molecule of 16,569 base pairs. It encodes 37 genes: 13 protein-coding genes (all encoding subunits of the oxidative phosphorylation complexes), 22 transfer RNAs, and 2 ribosomal RNAs. The genome is extremely compact, containing no introns, minimal intergenic sequences, and overlapping reading frames. It uses a slightly modified genetic code in which UGA codes for tryptophan rather than serving as a stop codon. The heavy (H) strand encodes 12 of the 13 polypeptides and most tRNAs, while the light (L) strand encodes one polypeptide (ND6) and 8 tRNAs. The D-loop (displacement loop) is a non-coding control region containing the origin of H-strand replication and the promoters for transcription.

Oxidative Phosphorylation (OXPHOS) System

The oxidative phosphorylation system consists of five multisubunit enzyme complexes (I through V) embedded in the inner mitochondrial membrane. Complexes I, III, IV, and V contain subunits encoded by both mitochondrial and nuclear DNA. Complex II (succinate dehydrogenase) is unique in being entirely nuclear-encoded. The mtDNA-encoded subunits include 7 in Complex I (ND1 through ND6 and ND4L), 1 in Complex III (cytochrome b), 3 in Complex IV (COX I through III), and 2 in Complex V (ATP6 and ATP8). Over 1,500 nuclear genes contribute to mitochondrial structure and function, meaning that the nuclear genome plays the dominant role in mitochondrial biology.

mtDNA Replication and Mutation Rate

Mitochondrial DNA is replicated by DNA polymerase gamma (POLG), which is nuclear-encoded. The mtDNA lacks protective histones and has limited DNA repair capacity, resulting in a mutation rate approximately 10 to 17 times higher than nuclear DNA. Each cell contains hundreds to thousands of mitochondria, and each mitochondrion carries 2 to 10 copies of mtDNA. The total mtDNA copy number per cell ranges from approximately 100 to 10,000, depending on tissue type and energy demands.

Maternal Inheritance

Principles

Mitochondrial DNA is inherited exclusively from the mother through the oocyte cytoplasm. Sperm contribute negligible mitochondria (roughly 100 compared to approximately 100,000 in the oocyte), and paternal mitochondria are actively degraded after fertilization through ubiquitin-proteasome and autophagy pathways. An affected mother transmits the variant to all of her offspring, meaning 100% of children are at risk. An affected father does not transmit mitochondrial variants to any offspring. Extremely rare reports of paternal mtDNA transmission exist but remain controversial and are not clinically significant.

Pedigree Characteristics

The maternal transmission pattern produces a distinctive pedigree in which affected individuals cluster along the maternal lineage. Both males and females are equally affected, unlike X-linked conditions. Males cannot transmit the variant to any offspring, unlike autosomal conditions. The pedigree can appear to "skip" generations when heteroplasmy levels in an intervening generation fall below the disease threshold.

Heteroplasmy and Threshold Effect

Heteroplasmy

Heteroplasmy refers to the coexistence of wild-type and mutant mtDNA within a cell, tissue, or individual. Homoplasmy describes the state in which all mtDNA copies are identical, either all wild-type or all mutant. Some pathogenic mtDNA variants are homoplasmic, such as m.11778G>A in Leber hereditary optic neuropathy (LHON); in these cases, disease manifestation depends on nuclear modifier genes, environmental factors, and sex. Heteroplasmy levels can vary between tissues within the same individual and can shift over time.

Threshold Effect

The threshold effect describes the minimum proportion of mutant mtDNA required to cause biochemical and clinical dysfunction. This threshold varies by tissue, with tissues that have high energy demands generally having lower thresholds. For the central nervous system, the threshold is approximately 60 to 70%. For skeletal muscle and kidney, it is roughly 70 to 80%. For the heart and liver, it falls between 60 and 80%. The threshold also varies by specific mutation and the degree of biochemical impairment produced.

Mitochondrial Genetic Bottleneck

During oogenesis, a sharp reduction in mtDNA copy number occurs in primordial germ cells, dropping to approximately 200 copies. This is followed by rapid amplification during oocyte maturation. This bottleneck can cause dramatic shifts in heteroplasmy levels between mother and offspring. A mother with low heteroplasmy may have an offspring with high heteroplasmy, and vice versa, making genetic counseling for recurrence risk extremely challenging.

Major Mitochondrial Disorders

MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes)

MELAS is most commonly caused by m.3243A>G in MT-TL1 (tRNA-Leu), which accounts for approximately 80% of cases. Onset is typically between ages 2 and 15 years. The stroke-like episodes are metabolic rather than embolic in origin and characteristically do not follow vascular territories. Additional features include seizures, migraines, diabetes mellitus, sensorineural hearing loss, short stature, and cardiomyopathy. Lactic acidosis occurs during acute episodes. Muscle biopsy reveals ragged red fibers on modified Gomori trichrome staining and SDH-positive, COX-negative fibers. Notably, the m.3243A>G variant at lower heteroplasmy levels is also associated with maternally inherited diabetes and deafness (MIDD).

MERRF (Myoclonus Epilepsy with Ragged Red Fibers)

MERRF is most commonly caused by m.8344A>G in MT-TK (tRNA-Lys), accounting for approximately 80% of cases. The clinical picture includes myoclonus, generalized seizures, cerebellar ataxia, and myopathy. Additional features include lipomas (especially multiple symmetric lipomatosis), sensorineural hearing loss, and dementia. Ragged red fibers are seen on muscle biopsy.

LHON (Leber Hereditary Optic Neuropathy)

Three primary mutations account for roughly 90% of LHON cases: m.11778G>A in ND4 (approximately 70%), m.3460G>A in ND1 (approximately 13%), and m.14484T>C in ND6 (approximately 14%). These variants are typically homoplasmic, and penetrance is incomplete, with approximately 50% of males and 15% of females developing vision loss. The presentation is acute or subacute painless bilateral sequential vision loss, usually in young adults aged 15 to 35. Males are more commonly affected, and nuclear modifier genes on the X chromosome may contribute to this sex difference. Idebenone, a synthetic CoQ10 analog, may be beneficial if initiated early, and gene therapy with lenadogene nolparvovec has been approved in Europe for the m.11778G>A variant.

Leigh Syndrome (Subacute Necrotizing Encephalomyelopathy)

Leigh syndrome is genetically heterogeneous and can be caused by mtDNA variants (such as MT-ATP6 m.8993T>G/C) or by variants in over 75 nuclear genes. Onset is typically in infancy or early childhood. The clinical course involves progressive neurological deterioration with developmental regression, hypotonia, respiratory abnormalities, and feeding difficulties. Characteristic bilateral symmetric lesions in the basal ganglia and brainstem are seen on MRI. Mortality is high, and therapeutic options remain limited.

Kearns-Sayre Syndrome (KSS)

Kearns-Sayre syndrome is caused by large-scale single mtDNA deletions, typically ranging from 1.1 to 10 kilobases, with the "common deletion" of 4,977 base pairs being the most frequent. The diagnostic triad consists of onset before age 20, progressive external ophthalmoplegia, and pigmentary retinopathy, plus at least one of the following: cardiac conduction defects (which may require a pacemaker), cerebellar ataxia, or cerebrospinal fluid protein above 100 mg/dL. Single deletions are almost always sporadic with a very low recurrence risk of less than 5%. KSS should be distinguished from Pearson syndrome, which involves the same deletion but presents with sideroblastic anemia and pancreatic insufficiency in infancy.

NARP (Neuropathy, Ataxia, and Retinitis Pigmentosa)

NARP is caused by MT-ATP6 variants m.8993T>G or m.8993T>C. At heteroplasmy levels of 70 to 90%, the NARP phenotype manifests with peripheral neuropathy, ataxia, and retinitis pigmentosa. At heteroplasmy levels above 90%, a Leigh syndrome phenotype develops instead. This condition vividly demonstrates the correlation between heteroplasmy level and phenotypic severity within a single gene and variant.

Nuclear Gene Causes of Mitochondrial Disease

Categories

Nuclear genes causing mitochondrial disease fall into several functional categories. OXPHOS assembly factors include SURF1 (Complex IV assembly, causing Leigh syndrome) and BCS1L (Complex III, causing GRACILE syndrome). mtDNA maintenance genes include POLG (polymerase gamma, causing Alpers syndrome and progressive external ophthalmoplegia), TWINKLE (helicase, causing PEO), and the deoxyribonucleoside kinases DGUOK, TK2, and RRM2B, whose deficiency leads to mtDNA depletion syndromes. Mitochondrial translation machinery genes include GFM1, TSFM, and mitochondrial aminoacyl-tRNA synthetases such as AARS2, DARS2, and EARS2. CoQ10 biosynthesis genes, including COQ2, COQ4, COQ6, and COQ8A, are particularly important because these disorders are potentially treatable with CoQ10 supplementation. Mitochondrial dynamics genes include OPA1 (dominant optic atrophy), MFN2 (CMT2A), and DRP1 (encephalopathy).

Inheritance Patterns

Most nuclear mitochondrial genes follow autosomal recessive inheritance, though some follow autosomal dominant inheritance (OPA1, POLG for PEO). The clinical presentation may be indistinguishable from primary mtDNA disorders.

Diagnostic Approach

Clinical Assessment

Multi-system involvement affecting high-energy-demand tissues should raise suspicion for mitochondrial disease. Red flags include progressive external ophthalmoplegia, stroke-like episodes in a young person, exercise intolerance with lactic acidosis, sensorineural hearing loss, maternal diabetes and deafness, and characteristic MRI findings. Elevated lactate in blood or CSF is suggestive but not specific; a lactate-to-pyruvate ratio greater than 20 suggests mitochondrial dysfunction.

Laboratory Testing

Blood and urine metabolic studies should include lactate, pyruvate, amino acids (looking for elevated alanine), and organic acids (looking for elevated 3-methylglutaconic acid in some disorders). FGF-21 and GDF-15 are emerging serum biomarkers with improved specificity for mitochondrial myopathy. Muscle biopsy can reveal ragged red fibers on Gomori trichrome staining, ragged blue fibers on SDH staining, and COX-negative/SDH-positive fibers on combined staining, along with enzyme histochemistry of respiratory chain complexes. However, muscle biopsy is being increasingly replaced by genomic sequencing as the first-tier diagnostic test.

Molecular Testing

mtDNA sequencing and deletion/duplication analysis from blood is the initial molecular test, though it may miss tissue-specific heteroplasmy. If blood testing is negative and clinical suspicion remains high, mtDNA testing from muscle or urine epithelial cells should be pursued. Nuclear gene panels or whole exome/genome sequencing can evaluate nuclear-encoded mitochondrial disease genes. Heteroplasmy quantification is performed by digital droplet PCR or next-generation sequencing. An important consideration is that heteroplasmy levels in blood may decrease with age due to selection against mutant mtDNA in rapidly dividing cells; urine epithelial cells often better reflect muscle heteroplasmy levels.

Genetic Counseling Challenges

Recurrence Risk

Recurrence risk varies dramatically depending on the type of mtDNA variant. Homoplasmic variants are transmitted to 100% of offspring of an affected mother, but penetrance may be incomplete, as with LHON. Heteroplasmic variants have unpredictable transmission due to the bottleneck effect, with potential transmission ranging from 0 to 100%. Single large-scale mtDNA deletions are typically sporadic with less than 5% recurrence. Nuclear gene causes follow standard Mendelian inheritance, usually autosomal recessive with 25% recurrence. Empiric data suggest that mothers with heteroplasmy below 18% for m.8993T>G have low risk of severely affected offspring, while at above 60%, most offspring will be affected.

Reproductive Options

Preimplantation genetic testing with IVF is feasible for some mtDNA variants, as heteroplasmy can be measured in trophectoderm biopsy. Mitochondrial replacement therapy, sometimes called "three-parent IVF," uses techniques such as maternal spindle transfer or pronuclear transfer to prevent transmission of pathogenic mtDNA. This was legalized in the UK in 2015, though ethical debates continue. Oocyte donation eliminates maternal mtDNA transmission entirely. Prenatal diagnosis by CVS or amniocentesis has limited utility for heteroplasmic variants because heteroplasmy in chorionic villi or amniocytes may not predict postnatal tissue levels.

<image>A diagram of the human mitochondrial genome shown as a circular map. The 37 genes are arranged and color-coded by function: Complex I subunits (ND1-ND6, ND4L) in blue, Complex III (cytochrome b) in green, Complex IV (COX I-III) in orange, Complex V (ATP6, ATP8) in red, 22 tRNA genes as small labeled segments in yellow, 2 rRNA genes (12S, 16S) in purple, and the D-loop control region in gray. Key pathogenic variant positions are marked with arrows: m.3243A>G (MELAS), m.8344A>G (MERRF), m.8993T>G (NARP/Leigh), m.11778G>A (LHON), and the common 4,977 bp deletion region (KSS/Pearson) shown as a dashed arc.</image>

<image>A schematic illustrating the mitochondrial bottleneck and heteroplasmy shift across generations. A mother cell with moderate heteroplasmy (40% mutant, shown as red mitochondria among blue wild-type) is depicted. During oogenesis, the mtDNA copy number drops dramatically in primordial germ cells (shown as a funnel narrowing to ~200 copies). Random sampling leads to different heteroplasmy levels in mature oocytes (one with 10% mutant, one with 80% mutant, one with 50% mutant). The resulting offspring are shown with different phenotypes based on their heteroplasmy level relative to the biochemical threshold line (drawn at ~70%): below threshold = unaffected, near threshold = mildly affected, above threshold = severely affected.</image>

<image>A comparison panel showing muscle biopsy histopathology findings in mitochondrial disease. Four microscopy images: (1) Modified Gomori trichrome stain showing ragged red fibers with subsarcolemmal accumulation of abnormal mitochondria appearing as red-purple deposits. (2) SDH (succinate dehydrogenase) stain showing ragged blue fibers. (3) Combined COX/SDH stain showing COX-negative fibers (blue, indicating mitochondrial dysfunction) interspersed among COX-positive fibers (brown, normal). (4) Electron micrograph showing enlarged mitochondria with paracrystalline inclusions. Each panel is labeled with the stain name and key diagnostic feature.</image>

Clinical Pearls

Multi-system disease affecting the CNS, skeletal muscle, heart, endocrine organs, and sensorineural hearing should prompt consideration of mitochondrial disease regardless of inheritance pattern. Blood heteroplasmy levels for mtDNA variants, especially m.3243A>G, decrease over time due to counter-selection in rapidly dividing cells; urine epithelial cells provide a more stable and representative measurement. Single large-scale mtDNA deletions (KSS/Pearson) are almost always sporadic with very low recurrence risk, in contrast to point mutations which follow maternal inheritance. Leigh syndrome is genetically heterogeneous with over 75 nuclear genes implicated, and genome sequencing should be pursued even when mtDNA testing is negative. CoQ10 biosynthesis defects (COQ2, COQ4, COQ6, COQ8A) are among the most treatable mitochondrial disorders; high-dose CoQ10 supplementation can be life-saving if initiated early. Sodium valproate should be avoided in patients with POLG mutations and in suspected mitochondrial disease in general due to the risk of fatal hepatotoxicity. The "mito cocktail" (CoQ10, riboflavin, L-carnitine, alpha-lipoic acid) is widely used but lacks strong evidence of efficacy for most mitochondrial disorders, with CoQ10 biosynthesis defects being the notable exception.

References

• Gorman GS et al. Mitochondrial diseases. Nat Rev Dis Primers. 2016;2:16080.
• Ng YS, Turnbull DM. Mitochondrial disease: genetics and management. J Neurol. 2016;263(1):179-191.
• Stenton SL, Prokisch H. Genetics of mitochondrial diseases: identifying mutations to help diagnosis. EBioMedicine. 2020;56:102784.
• Craven L et al. Mitochondrial DNA disease: new options for prevention. Hum Mol Genet. 2017;26(R2):R137-R144.
• Rahman J, Rahman S. Mitochondrial medicine in the omics era. Lancet. 2018;391(10139):2560-2574.
• Schon EA et al. Mitochondrial diseases: a diagnostic revolution. Trends Genet. 2020;36(9):702-717.

Read this lecture as Markdown